Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials.

Hua X, Hibar DP, Ching CR, Boyle CP, Rajagopalan P, Gutman BA, Leow AD, Toga AW, Jack CR Jr, Harvey D, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2013 Feb 1;66:648-61. doi: 10.1016/j.neuroimage.2012.10.086. Epub 2012 Nov 12.

2.

Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects.

Hua X, Lee S, Yanovsky I, Leow AD, Chou YY, Ho AJ, Gutman B, Toga AW, Jack CR Jr, Bernstein MA, Reiman EM, Harvey DJ, Kornak J, Schuff N, Alexander GE, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2009 Dec;48(4):668-81. doi: 10.1016/j.neuroimage.2009.07.011. Epub 2009 Jul 14.

3.

MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials.

Hua X, Ching CRK, Mezher A, Gutman BA, Hibar DP, Bhatt P, Leow AD, Jack CR Jr, Bernstein MA, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2016 Jan;37:26-37. doi: 10.1016/j.neurobiolaging.2015.09.018. Epub 2015 Oct 19.

4.

Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease.

Vemuri P, Senjem ML, Gunter JL, Lundt ES, Tosakulwong N, Weigand SD, Borowski BJ, Bernstein MA, Zuk SM, Lowe VJ, Knopman DS, Petersen RC, Fox NC, Thompson PM, Weiner MW, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2015 Jun;113:61-9. doi: 10.1016/j.neuroimage.2015.03.026. Epub 2015 Mar 20.

5.

Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals.

Hua X, Lee S, Hibar DP, Yanovsky I, Leow AD, Toga AW, Jack CR Jr, Bernstein MA, Reiman EM, Harvey DJ, Kornak J, Schuff N, Alexander GE, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2010 May 15;51(1):63-75. doi: 10.1016/j.neuroimage.2010.01.104. Epub 2010 Feb 6.

6.

Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry.

Ho AJ, Hua X, Lee S, Leow AD, Yanovsky I, Gutman B, Dinov ID, Leporé N, Stein JL, Toga AW, Jack CR Jr, Bernstein MA, Reiman EM, Harvey DJ, Kornak J, Schuff N, Alexander GE, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Hum Brain Mapp. 2010 Apr;31(4):499-514. doi: 10.1002/hbm.20882.

7.

Visual rating method and tensor-based morphometry in the diagnosis of mild cognitive impairment and Alzheimer's disease: a comparative magnetic resonance imaging study.

Tuokkola T, Koikkalainen J, Parkkola R, Karrasch M, Lötjönen J, Rinne JO.

Acta Radiol. 2016 Mar;57(3):348-55. doi: 10.1177/0284185115584656. Epub 2015 May 14.

PMID:
25977576
8.

Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.

Da X, Toledo JB, Zee J, Wolk DA, Xie SX, Ou Y, Shacklett A, Parmpi P, Shaw L, Trojanowski JQ, Davatzikos C; Alzheimer's Neuroimaging Initiative.

Neuroimage Clin. 2013 Nov 28;4:164-73. doi: 10.1016/j.nicl.2013.11.010. eCollection 2014.

9.

Does MRI scan acceleration affect power to track brain change?

Ching CR, Hua X, Hibar DP, Ward CP, Gunter JL, Bernstein MA, Jack CR Jr, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2015 Jan;36 Suppl 1:S167-77. doi: 10.1016/j.neurobiolaging.2014.05.039. Epub 2014 Oct 7.

10.

Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects.

Hua X, Leow AD, Parikshak N, Lee S, Chiang MC, Toga AW, Jack CR Jr, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2008 Nov 15;43(3):458-69. doi: 10.1016/j.neuroimage.2008.07.013. Epub 2008 Jul 22.

11.

Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition.

Leow AD, Yanovsky I, Parikshak N, Hua X, Lee S, Toga AW, Jack CR Jr, Bernstein MA, Britson PJ, Gunter JL, Ward CP, Borowski B, Shaw LM, Trojanowski JQ, Fleisher AS, Harvey D, Kornak J, Schuff N, Alexander GE, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2009 Apr 15;45(3):645-55.

12.

Lack of neural compensatory mechanisms of BDNF val66met met carriers and APOE E4 carriers in healthy aging, mild cognitive impairment, and Alzheimer's disease.

Gomar JJ, Conejero-Goldberg C, Huey ED, Davies P, Goldberg TE; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2016 Mar;39:165-73. doi: 10.1016/j.neurobiolaging.2015.12.004. Epub 2015 Dec 19.

PMID:
26923413
13.

Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration.

Leung KK, Bartlett JW, Barnes J, Manning EN, Ourselin S, Fox NC; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2013 Feb 12;80(7):648-54. doi: 10.1212/WNL.0b013e318281ccd3. Epub 2013 Jan 9.

14.

Studying ventricular abnormalities in mild cognitive impairment with hyperbolic Ricci flow and tensor-based morphometry.

Shi J, Stonnington CM, Thompson PM, Chen K, Gutman B, Reschke C, Baxter LC, Reiman EM, Caselli RJ, Wang Y; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2015 Jan 1;104:1-20. doi: 10.1016/j.neuroimage.2014.09.062. Epub 2014 Oct 5.

15.

Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD.

Jack CR Jr, Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Cha RH, Tangalos EG, Petersen RC.

Neurology. 2004 Feb 24;62(4):591-600.

16.

Genetic influence of apolipoprotein E4 genotype on hippocampal morphometry: An N = 725 surface-based Alzheimer's disease neuroimaging initiative study.

Shi J, Leporé N, Gutman BA, Thompson PM, Baxter LC, Caselli RJ, Wang Y; Alzheimer's Disease Neuroimaging Initiative.

Hum Brain Mapp. 2014 Aug;35(8):3903-18. doi: 10.1002/hbm.22447. Epub 2014 Jan 22.

17.

Structural Brain Changes in Early-Onset Alzheimer's Disease Subjects Using the LONI Pipeline Environment.

Moon SW, Dinov ID, Hobel S, Zamanyan A, Choi YC, Shi R, Thompson PM, Toga AW; Alzheimer's Disease Neuroimaging Initiative.

J Neuroimaging. 2015 Sep-Oct;25(5):728-37. doi: 10.1111/jon.12252. Epub 2015 May 4.

18.

Neuroimaging basis in the conversion of aMCI patients with APOE-ε4 to AD: study protocol of a prospective diagnostic trial.

Chen GQ, Sheng C, Li YX, Yu Y, Wang XN, Sun Y, Li HY, Li XY, Xie YY, Han Y.

BMC Neurol. 2016 May 12;16:64. doi: 10.1186/s12883-016-0587-2.

19.

Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease.

Kennedy RE, Cutter GR, Schneider LS.

Alzheimers Dement. 2014 May;10(3):349-59. doi: 10.1016/j.jalz.2013.03.003. Epub 2013 May 25.

20.

Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database.

Nestor SM, Rupsingh R, Borrie M, Smith M, Accomazzi V, Wells JL, Fogarty J, Bartha R; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2008 Sep;131(Pt 9):2443-54. doi: 10.1093/brain/awn146. Epub 2008 Jul 11.

Supplemental Content

Support Center